百奥赛图合作伙伴IDEAYA举办十周年研发日，携手推进双抗ADC联合治疗新篇章

新浪证券2025-09-19

百奥赛图祝贺合作伙伴IDEAYA Biosciences的十周年研发日在9月8日圆满举行。IDEAYA在会上公布了多项研发进展，其中重点提及了双方合作的B7-H3/PTK7双特异性抗体偶联药物（bsADC）IDE034（BCG034）。该项目的推进展示了新一代双抗ADC药物与小分子抑制剂联合应用的潜力，为精准肿瘤治疗开辟了新的组合策略。IDE034是由百奥赛图自主研发的RenLite®共轻链平台...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2568925200?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-09-19 15:39","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2568925200","market":"hk","top_or_hot":-1,"title":"百奥赛图合作伙伴IDEAYA举办十周年研发日，携手推进双抗ADC联合治疗新篇章","media":"新浪证券","content":"<div>\n<p>百奥赛图祝贺合作伙伴IDEAYA Biosciences的十周年研发日在9月8日圆满举行。IDEAYA在会上公布了多项研发进展，其中重点提及了双方合作的B7-H3/PTK7双特异性抗体偶联药物（bsADC）IDE034（BCG034）。该项目的推进展示了新一代双抗ADC药物与小分子抑制剂联合应用的潜力，为精准肿瘤治疗开辟了新的组合策略。IDE034是由百奥赛图自主研发的RenLite®共轻链平台...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250919153930a436a446&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百奥赛图合作伙伴IDEAYA举办十周年研发日，携手推进双抗ADC联合治疗新篇章</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百奥赛图合作伙伴IDEAYA举办十周年研发日，携手推进双抗ADC联合治疗新篇章\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-19 15:39 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250919153930a436a446&s=b><strong>新浪证券</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>百奥赛图祝贺合作伙伴IDEAYA Biosciences的十周年研发日在9月8日圆满举行。IDEAYA在会上公布了多项研发进展，其中重点提及了双方合作的B7-H3/PTK7双特异性抗体偶联药物（bsADC）IDE034（BCG034）。该项目的推进展示了新一代双抗ADC药物与小分子抑制剂联合应用的潜力，为精准肿瘤治疗开辟了新的组合策略。IDE034是由百奥赛图自主研发的RenLite®共轻链平台...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250919153930a436a446&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02315","symbol_name":"百奥赛图-B","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250919153930a436a446&s=b","article_id":"2568925200","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250919153930a436a446&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2568925200","pubTimestamp":1758267540,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"百奥赛图祝贺合作伙伴IDEAYA Biosciences的十周年研发日在9月8日圆满举行。IDEAYA在会上公布了多项研发进展，其中重点提及了双方合作的B7-H3/PTK7双特异性抗体偶联药物IDE034。IDEAYA预计将在2025年第四季度完成IND申报，预期适应症覆盖肺癌、结直肠癌、头颈鳞癌及卵巢癌患者群体。百奥赛图在双抗ADC研发领域拥有领先优势。随着全球研发趋势逐步迈向多元化与组合化，ADC与小分子药物的联合治疗正日益成为重要方向。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02315":"百奥赛图-B","BK1161":"生物科技"},"translate_title":"Biocyto partner IDEAYA held its 10th anniversary R&D day to jointly promote a new chapter in dual-antibody ADC combination therapy","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02315":0.9},"content_text":"百奥赛图祝贺合作伙伴IDEAYA Biosciences的十周年研发日在9月8日圆满举行。IDEAYA在会上公布了多项研发进展，其中重点提及了双方合作的B7-H3/PTK7双特异性抗体偶联药物（bsADC）IDE034（BCG034）。该项目的推进展示了新一代双抗ADC药物与小分子抑制剂联合应用的潜力，为精准肿瘤治疗开辟了新的组合策略。IDE034是由百奥赛图自主研发的RenLite®共轻链平台筛选获得，可同时识别B7-H3与PTK7两个肿瘤相关靶点，实现双靶点协同作用，提升药物选择性和抗肿瘤效率。其所搭载的是公司专有的新型Linker & Payload平台BLD1102（拓扑异构酶抑制剂），可与IDEAYA的DNA损伤反应（DDR）抑制剂形成协同作用，进一步增强组合疗效。临床前数据显示，IDE034在B7-H3低表达同时PTK7高表达的CDX肿瘤模型中展现出显著抑瘤效果；与PARG抑制剂IDE161联合使用时，进一步释放了强大的肿瘤特异性协同作用。IDEAYA预计将在2025年第四季度完成IND申报，预期适应症覆盖肺癌、结直肠癌、头颈鳞癌及卵巢癌患者群体。百奥赛图在双抗ADC研发领域拥有领先优势。RenLite平台可产生共轻链全人抗体，有效避免轻重链错配，降低CMC工艺难度，提高研发成功率。RenNano®平台可高效开发全人纳米抗体，为双抗/多抗、ADC及细胞治疗等领域提供灵活的设计元件。同时，公司“千鼠万抗”依托RenMice®系列全人抗体/TCR小鼠平台，已建立超过100万全人抗体库，覆盖上千潜在药物靶点，为快速匹配和验证新型双靶点组合提供了坚实保障。凭借在双抗ADC领域的技术和平台能力，百奥赛图已获得多家全球合作伙伴的认可，包括SOTIO、ABL Bio、Radiance及ADC Therapeutics等。同时，“千鼠万抗”在更广泛的创新药研发中，也达成了与吉利德、Merck KGaA， Darmstadt， Germany、强生旗下杨森在内的TOP10中7家跨国药企的抗体合作。随着全球研发趋势逐步迈向多元化与组合化，ADC与小分子药物的联合治疗正日益成为重要方向。未来，公司将依托持续的技术创新与高质量全人抗体分子，推动更多差异化创新药物的诞生，为全球肿瘤患者提供更具选择性和疗效的治疗方案，并致力于打造全球新药的发源地。责任编辑：郭栩彤","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2568925200","isCrawlerRequest":true}